Usana Health Sciences shares fell 30% this week after the company reported second-quarter earnings and revenue well below analyst expectations and lowered its full-year outlook. Adjusted earnings per share came in at $0.07, missing the consensus estimate by $0.50, while revenue of roughly $223 million was about $12 million below forecasts. The company also announced a $29 million goodwill impairment charge on its Hiya business, leading it to now expect a full-year loss of approximately $11 million, down from prior guidance for a profit between $20 million and $27 million. Full-year sales guidance was reduced from a range of $925 million to $1 billion to $910 million, reflecting weaker performance in the Hiya and Rise segments despite some stabilization in the core nutrition business.
USANA Health Sciences IncQ2 earnings and revenue missed estimates, and the company lowered full-year guidance, including a shift to a projected loss.
